Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications

Claudio Fozza; Andrea Murtas; Giovanni Caocci; Giorgio La Nasa

doi:10.1016/j.leukres.2022.106856

Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications

Leuk Res. 2022 Jun:117:106856. doi: 10.1016/j.leukres.2022.106856. Epub 2022 May 2.

Authors

Claudio Fozza¹, Andrea Murtas¹, Giovanni Caocci², Giorgio La Nasa²

Affiliations

¹ Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
² Department of Medical Sciences, University of Cagliari, Cagliari, Italy.

PMID: 35525186
DOI: 10.1016/j.leukres.2022.106856

Abstract

Around one third of patients with myelodysplastic syndromes (MDS) suffer from concomitant autoimmune disorders (AD). However the actual burden of such an association appears to be quite heterogeneous in different studies probably due to variable criteria in selecting both MDS patients and subtypes of AD. Moreover, both the prognostic implications and the potential applications of specific therapeutic approaches in this patient subgroup are still at least partially under debate. The present review will try to shed some further light on the clinical association between MDS and AD in order to better delineate its prognostic significance and to suggest potential therapeutic algorithms available for these patients.

Keywords: Autoimmune manifestations; Autoimmunity; Immunotherapy; Myelodysplastic syndromes.

Publication types

Review

MeSH terms

Autoimmune Diseases* / complications
Autoimmune Diseases* / therapy
Humans
Myelodysplastic Syndromes* / complications
Myelodysplastic Syndromes* / diagnosis
Myelodysplastic Syndromes* / therapy
Prognosis